How long does semaglutide (Ozempic, Wegovy) stay in your system?

Semaglutide has a half-life of roughly 1 week (~160 hours). Following the standard 5-half-lives rule for near-complete clearance, most of the drug is gone about 5 weeks after the last dose.

How long does tirzepatide (Mounjaro, Zepbound) stay in your system?

Tirzepatide has a shorter half-life of about 5 days. Near-complete clearance takes roughly 3–4 weeks after the last dose, which is why the appetite rebound tends to arrive sooner than with semaglutide.

How quickly does appetite come back after stopping?

Most people describe noticeably stronger hunger within days to a couple of weeks of the last dose, well before the drug is fully cleared. Published trial curves for subjective appetite return post-cessation don't exist — this timing is based on user reports and physiology, not measured data.

What's the difference between hunger returning and 'food noise' returning?

Hunger is the physical sensation; 'food noise' is the mental preoccupation many people describe as quieted by GLP-1s. In practice, physical hunger tends to return first as the drug clears, while food noise often re-emerges over a longer window as reward pathways recalibrate.

Does the higher your dose was affect how long suppression lasts?

Higher doses mean higher steady-state drug levels, so residual appetite suppression may persist marginally longer as levels decay — but the half-life itself doesn't change with dose. The dominant driver of timing is which drug you were on, not which dose.

Is this the same for orforglipron (Foundayo)?

No. Orforglipron is a once-daily oral drug and clears far faster than the weekly injectables — most of it is gone within a few days of the last dose. That's part of what makes it a candidate for maintenance-phase use, but it also means the appetite rebound arrives quickly.

GLP-1 Appetite Suppression: How Long It Lasts

Written by the GLP-1 Coach editorial team. Last updated August 13, 2026.

Of all the questions people search once they're thinking about stopping a GLP-1, this is the one with the most concrete answer — and the one where the most confident-sounding content online is actually the least honest about where the data ends.

The pharmacokinetics are well-measured. When appetite subjectively comes back, and when "food noise" returns, isn't. Here's what's actually known.

How long does semaglutide stay in your system after your last dose?

Semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) has an unusually long half-life for an injectable drug — approximately 1 week (~160 hours) according to the FDA prescribing information. The half-life is what makes the once-weekly dosing schedule possible in the first place.

Applying the standard pharmacology convention that a drug is considered "cleared" after about 5 half-lives:

Time since last dose	Approximate % of drug remaining
1 week	~50%
2 weeks	~25%
3 weeks	~12.5%
4 weeks	~6%
5 weeks	~3% (functionally cleared)

That's the reason clinical protocols requiring GLP-1 washout — for example, Novo Nordisk's guidance to stop semaglutide at least 2 months before a planned pregnancy — build in a wide safety margin beyond the strict 5-half-lives window.

The important nuance: residual drug level does not equal residual clinical effect at the same ratio. By week 2 or 3, drug levels are already well below the threshold that produces meaningful appetite suppression for most people, even though there's still detectable semaglutide in the system.

How long does tirzepatide stay in your system?

Tirzepatide (Mounjaro, Zepbound) has a shorter half-life of about 5 days. The math works out to roughly 3–4 weeks for near-complete clearance:

Time since last tirzepatide dose	Approximate % remaining
5 days	~50%
10 days	~25%
15 days	~12.5%
20 days	~6%
25 days	~3% (functionally cleared)

The practical consequence: appetite tends to rebound noticeably faster after stopping tirzepatide than after stopping semaglutide. Most people transitioning off a weekly tirzepatide dose describe a distinct return of hunger within roughly one to two weeks, whereas semaglutide-transitioners often report a slower drift over two to four weeks.

Neither drug produces a "wall" where suppression is fully present one day and gone the next. Both taper off along with their pharmacokinetic curves.

When does hunger actually come back?

This is where the confident-sounding numbers stop being honest.

There is no published clinical trial that has tracked subjective appetite return week by week after GLP-1 cessation with validated instruments. The commonly cited "7 to 10 days" or "2 to 3 weeks" figures come from clinic content, telehealth marketing pages, and social media reports — not peer-reviewed data.

What the physiology reasonably predicts, and what real-world reports converge on:

Days 3–7 post-dose: subtle uptick in appetite as drug levels drop below their weekly steady-state peak — often not consciously noticed.
Weeks 1–2: more distinctly increased hunger, particularly the mid-afternoon and evening windows that tend to be quietest on active treatment.
Weeks 2–4: appetite drifts closer to pre-treatment baseline. Ghrelin — the "hunger hormone" that GLP-1s partly work around — rebounds toward, and sometimes briefly overshoots, baseline.
Weeks 4–8: for most people, appetite regulation is back to roughly what it was before treatment. Weight trajectory in this window is a strong predictor of longer-term regain patterns (see the STEP-1 extension data below).

The important framing: the return of hunger is not a failure of the medication or of willpower. It is the direct, expected physiological consequence of removing an appetite-suppressing drug from your system.

Is "food noise" different from hunger — and does it come back on the same schedule?

Yes, and often no.

"Food noise" is the informal term many GLP-1 users adopt for the mental preoccupation with food that many describe as quieted or absent on the medication. It's not the same as hunger; it's closer to intrusive thoughts about what to eat next, food cravings between meals, and the ambient mental load of thinking about food throughout the day.

In practice, users commonly report that:

Physical hunger returns first, tracking roughly with drug clearance.
Food noise returns more gradually and less predictably, sometimes not fully re-emerging until 4–8 weeks post-cessation, sometimes returning in the first week.

The mechanism is less well-characterized than pure appetite regulation — GLP-1s appear to affect dopamine reward pathways in addition to hunger signaling, and that recalibration timeline is not straightforward. Anyone who tells you "food noise comes back at exactly week X" is guessing.

What does the weight trajectory look like in the weeks after suppression fades?

The most useful reference point is the STEP-1 extension study, published in Diabetes, Obesity and Metabolism in 2022. Participants who had lost an average of 17.3% of body weight on semaglutide 2.4 mg over 68 weeks were followed for another year off medication.

By week 120 (roughly one year after the last dose), participants had regained about 11.6 percentage points of that loss — leaving a net loss of about 5.6% from their original starting weight. Roughly two-thirds of the weight lost on the drug was regained within a year of stopping it, and the trajectory of that regain tracked closely with the return of appetite regulation.

The comparable data for tirzepatide comes from SURMOUNT-4, published in JAMA in 2023: after a 36-week lead-in on tirzepatide, participants who continued the drug lost an additional 5.5% of body weight over the next year, while those switched to placebo regained about 14 percentage points. The gap between groups was roughly a 20-percentage-point swing driven almost entirely by the removal of the drug.

Neither of these trials measured when appetite subjectively returned. But both confirm the pattern: the appetite curve and the weight curve move together, and both start moving within weeks of the last dose.

What actually happens with GI side effects after stopping?

The nausea, early fullness, constipation, and other GI side effects that many people experience on GLP-1s tend to resolve within days of the last dose — often faster than most people expect. GI side effects are among the first things to fade because they're mediated by ongoing gastric slowing and vagal signaling, both of which normalize quickly as drug levels drop.

This is one of the few unambiguously "easy" parts of stopping: the day-to-day medication side effect burden drops off quickly, well before appetite regulation shifts.

The bottom line

Bottom line: Semaglutide takes about 5 weeks to clear your system; tirzepatide takes about 3–4 weeks. Hunger tends to return distinctly within 1–2 weeks and drift back to baseline over 4–8 weeks. Food noise returns on a less predictable, more gradual schedule. Published week-by-week data on subjective appetite return doesn't exist — anyone quoting exact timelines is inferring from physiology, not measuring it.

Related tool: our free post-therapy timeline calculator applies these pharmacokinetics to your specific last-dose date.

Final Thoughts

The appetite-return window is the highest-leverage stretch of the entire post-medication phase. It's where habits built during active treatment either carry the weight loss forward or don't, and it's the window where the STEP-1 and SURMOUNT-4 data show the regain trajectory begins.

If you're still on medication and thinking about stopping, the most useful thing you can do isn't figuring out the exact week your appetite will come back — nobody actually knows that. It's making sure the protein habits, meal structure, and resistance activity that will still be there in week 6 are already in place while the medication is still doing its work.

If you're already off medication and noticing hunger and food noise returning, that's not a sign anything is wrong. It's the expected timeline for a drug clearing your system. The question is whether the structure you built during treatment is doing what it was supposed to do.

This article is educational and not a substitute for medical advice. Decisions about stopping, tapering, or restarting any GLP-1 medication should be made with the prescriber managing your care.

Sources: Wegovy prescribing information, FDA; Wilding et al., STEP 1 extension, Diabetes, Obesity and Metabolism 2022; Aronne et al., SURMOUNT-4, JAMA 2023; Mounjaro prescribing information, Eli Lilly.